Professional Documents
Culture Documents
Open
en Journal of Human Hypertension (2010) 24, 918
& 2010 Macmillan Publishers Limited All rights reserved 0950-9240/10 $32.00
www.nature.com/jhh
ORIGINAL ARTICLE
The epidemiology and management
of severe hypertension
AM Borzecki1,2,3, B Kader1,2 and DR Berlowitz1,2,3
1
Center for Health Quality Outcomes and Economic Research, Bedford VAMC, Bedford, MA, USA;
2
Department of Health Policy and Management, Boston University School of Public Health, Boston, MA, USA
and 3Section of General Internal Medicine, Boston University School of Medicine, Boston, MA, USA
Hypertension guidelines stress that patients with severe (range 1548). These subjects were significantly older,
hypertension (systolic blood pressure (BP)X180 more likely black, and with more comorbidities than other
or diastolic BPX110 mm Hg) require multiple drugs to hypertension subjects. Medication increases occurred at
achieve control and should have close follow-up 20% of visits with mild hypertension compared to 40%
to prevent adverse outcomes. However, little is known with severe hypertension; Po0.05). At study end, 76% of
about the epidemiology or actual management of these patients with severe hypertension remained uncontrolled;
patients. We retrospectively studied 59 207 veterans severe hypertension subjects with uncontrolled BP were
with hypertension. Patients were categorized based on less likely to be on adequate therapy than those with
their highest average BP over an 18-month period controlled BP (43.7 vs 45.4%). Among hypertensive
(1 July 1999 to 31 December 2000) as controlled veterans, severe hypertension episodes are common.
(o140/90 mm Hg), mild (140159/9099 mm Hg), moderate Many subjects had relatively prolonged elevations, with
(160179/100109 mm Hg) and severe hypertension. We older, sicker subjects at highest risk. Although, follow-up
examined severe hypertension prevalence, pattern, dura- times are shorter and antihypertensive medication use
tion, associated patient characteristics, time to subse- greater in severe hypertension subjects, they are still
quent visit, percentage of visits with a medication not being managed aggressively enough. Interventions
increase, and final BP control and antihypertensive to improve providers management of these high-risk
medication adequacy. Twenty-three per cent had X1 visit patients are needed.
with severe hypertension, 42% of whom had at least two Journal of Human Hypertension (2010) 24, 918;
such visits; median day with severe hypertension was 80 doi:10.1038/jhh.2009.37; published online 14 May 2009
Age, mean (s.d.), years 63.7 (11.3) 63.8 (11.2) 65.5 (10.9) 67.0 (10.8)a
Gender, female, no. (%) 121 (2.3) 516 (2.7) 604 (2.9) 453 (3.3)a
Race, no. (%), white 3988 (77.1) 14 563 (75.5) 15 573 (74.1) 9545 (69.5)a
Black 659 (12.8) 2,842 (14.7) 3,741 (17.8) 3302 (24.0)a
Hispanic 71 (1.4) 233 (1.2) 300 (1.4) 153 (1.1)
Others 108 (2.1) 358 (1.9) 341 (1.6) 221 (1.6)
Unknown 344 (6.7) 1294 (6.7) 1057 (5.0) 514 (3.7)a
BMI, mean (s.d.), kg m2 28.8 (5.4) 29.4 (5.5) 29.5 (5.8) 29.2 (6.1)a
Comorbidities
Cerebrovascular disease, no. (%) 669 (12.9) 2261 (11.7) 2781 (13.2) 2305 (16.8)a
Congestive heart failure, no. (%) 1055 (20.4) 2338 (12.1) 2354 (11.2) 1814 (13.2)a
Coronary artery disease, no. (%) 2392 (46.3) 6998 (36.3) 7128 (33.9) 4802 (35.0)a
Diabetes, no. (%) 1584 (30.6) 5841 (30.3) 6996 (33.3) 5263 (38.3)a
Hyperlipidaemia, no. (%) 2563 (49.6) 8927 (46.3) 8895 (42.3) 5151 (37.5)a
Peripheral vascular disease, no. (%) 532 (10.3) 1688 (8.8) 2141 (10.2) 1760 (12.8)a
Renal disease, no. (%) 340 (6.6) 1050 (5.4) 1378 (6.6) 1430 (10.4)a
Tobacco use, no. (%) 503 (9.7) 1897 (9.8) 1951 (9.3) 1219 (8.9)a
Charlson index, mean (s.d.) 1.3 (1.4) 1.2 (1.2) 1.2 (1.2) 1.4 (1.3)a
Age, mean (s.d.), years 67.4 (10.8) 67.7 (10.6) 66.6 (10.9)a
Gender, female, no. (%) 80 (3.2) 104 (3.2) 269 (3.4) NS
Race, no. (%), white 1631 (64.8) 2144 (66.8) 5770 (72.1)a
Black 734 (29.2) 910 (28.4) 1658 (20.7)a
Hispanic 26 (1.0) 42 (1.3) 85 (1.1)
Others 40 (1.6) 40 (1.3) 141 (1.8)
Unknown 86 (3.4) 74 (2.3) 354 (4.4)a
BMI, mean (s.d.), kg m2 29.2 (6.1) 29.0 (6.1) 29.4 (6.1)a
Comorbidities
Cerebrovascular disease, no. (%) 470 (18.7) 612 (19.1) 1223 (15.3)a
Congestive heart failure, no. (%) 350 (13.9) 490 (15.3) 974 (12.2)a
Coronary artery disease, no. (%) 834 (33.1) 1217 (37.9) 2751 (34.4)a
Diabetes, no. (%) 1064 (42.3) 1396 (43.5) 2803 (35.0)a
Hyperlipidaemia, no. (%) 912 (36.2) 1178 (36.7) 3061 (38.2)a
Peripheral vascular disease, no. (%) 323 (12.8) 514 (16.0) 923 (11.5)a
Renal disease, no. (%) 291 (11.6) 465 (14.5) 674 (8.4%)a
Tobacco use, no. (%) 211 (8.4%) 287 (8.9%) 721 (9.0) NS
Charlson index, mean (s.d.) 1.4 (1.3) 1.6 (1.4) 1.3 (1.3)a
Abbreviations: BMI, body mass index; NS, not significant; s.d., standard deviation.
a
Po0.05 for among-group comparisons and pair-wise comparisons; recurrent and persistent groups were similar with respect to age, white and
black race distribution, BMI, prevalence of cerebrovascular disease, congestive heart failure, diabetes and hyperlipidaemia.
Controlled (N 5170) 0.2 (0.10.4) 0.6 (0.40.8) 9.0 (8.29.8) 1.5 (1.21.7) 10.6 (9.811.5)
Mild (N 19 290) 0.3 (0.20.4) 0.9 (0.81.1) 8.6 (8.29.0) 1.6 (1.41.8) 10.8 (10.311.2)
Moderate (N 21 012) 0.4 (0.30.5) 1.7 (1.51.8) 8.6 (8.28.9) 1.9 (1.72.1) 11.5 (11.112.0)
Severe (N 13 735) 0.8 (0.71.0) 3.7 (3.44.0) 8.9 (8.49.4) 2.2 (2.02.5) 14.1 (13.614.7)
Persistent (N 2517) 1.2 (0.91.7) 4.6 (3.85.5) 7.2 (6.38.3) 2.5 (1.93.1) 13.7 (12.415.1)
Recurrent (N 3210) 1.0 (0.71.4) 6.2 (5.47.1) 11.7 (10.612.8) 2.8 (2.33.4) 19.4 (18.015.1)
Isolate spike (N 8008) 0.7 (0.50.9) 2.4 (2.12.7) 8.3 (7.89.0) 2.0 (1.72.3) 12.2 (11.512.9)
for between-group differences). The frequency of a with a BP were excluded from this analysis; 500 had
code for secondary hypertension ranged from 0% controlled, 525 had mild, 243 had moderate and 122
among endocrinology visits, 0.1% for cardiology, (9%) had severe hypertension. We found similar
0.9% for renal, to 2.8% of all hypertension clinic results to those reported below if we included these
visits. subjects in analyses and assumed they had an
When categorized by the highest available BP additional visit and their BP category was stable
before the last visit of the study, at the end of study (data not shown; available from authors).)
24% of the severe hypertension group had con- At the end of study, the mean number of BP
trolled BP, compared to 73% of the controlled, 51% medications increased significantly with increasing
of mild and 33% of the moderate group (Po0.05). BP category (Table 5; Figure 1). In addition, severe
For the severe hypertension subgroups, the isolated hypertension patients were significantly more likely
spike group was most likely to be controlled (27%), to be on all classes of antihypertensives compared to
followed by the recurrent (21%) and the persistent the other groups (Table 5). Among severe hyperten-
groups (16%; Po0.05 for between-group differ- sion subgroups, the persistent and recurrent sub-
ences). (Of note, 1390 subjects with only one visit groups were on more medications at study end than
Isolated spike
number of medications and the percentage on each medication class or on adequate therapy increased with increasing BP group, except for b-blocker use where the controlled group was more likely
and percentage on adequate therapy. For the severe hypertension subgroups, the mean number of medications, the percentage on each medication class or adequate therapy was significantly lower
to be on a b-blocker than the mild or moderate group. Also, the controlled and mild groups were not significantly different with respect to ACEI/ARB use, diuretic use, other vasodilators use
Po0.05 for among-group and pair-wise comparisons; analyses were carried out separately for the BP groups and severe hypertension subgroups. In pair-wise comparisons, for BP groups, the mean
for the isolated spike group than the persistent or recurrent, except for ACEI/ARB use which was similar to the recurrent. The persistent and recurrent groups were similar in all comparisons except
the isolated spike subgroup (Table 5; Po0.05 for
(56.2)a
(23.2)a
(33.7)a
(44.2)a
(46.7)a
(38.7)a
(1.3)a
(8.4)a
N 7431
between-group differences). The proportion on each
medication class was significantly lower for the
Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; CCBs, calcium channel blockers; s.d., standard deviation.
4173
1720
2504
3285
3473
2877
2.6
627
isolated spike group than the persistent or recurrent
group, except for ACEI/ARB use which was similar
to the recurrent group (Table 5). Despite a trend
towards higher use of each medication class among
the persistent group compared to the recurrent, the
(57.8)
(25.7)
(39.4)
(49.8)
(50.3)
(17.9)
(51.6)
Recurrent
(1.5)
1056
1333
1346
1383
3.2
688
479
study end (o140/90 mm Hg) were on more medica-
tions than those with uncontrolled BP (although this
difference was not significant for the severe hyper-
tension group; Figure 1). Within severe hyperten-
sion subgroups, the mean number of medications at
(61.8)
(25.3)
(41.3)
(50.4)
(51.3)
(18.6)
(52.9)
(1.5)
1142
1161
1197
3.2
572
934
421
2.8 (1.4)a
Severe
6018 (30.8)
N 19 528
2.3 (1.2)
938 (4.8)
Moderate
(48.9)
(20.3)
(29.8)
(34.1)
(39.0)
(23.7)
N 19 488
(2.8)
Mild
4608
548
2.1
(Figure 2).
Includes clonidine, hydralazine, methyldopa and minoxidil.
Discussion
(49.3)
(18.6)
(34.2)
(29.7)
(38.9)
(23.6)
(1.1)
(2.7)
1519
173
2.0
severe elevations.
CCBs, no. (%)
3.4
3.2
Mean No. BP Medications
3.0
2.8
Controlled
Uncontrolled
2.6
2.4
2.2
2.0
1.8
Controlled Mild Moderate Severe Persistent Recurrent Isolated Spike
BP Category
Figure 1 Mean number of antihypertensive medications at study end by highest preceding blood pressure (BP) category and final BP
control. Means shown with surrounding bars representing 95% confidence intervals. (Error bars overlap for those in the controlled BP
group with controlled vs uncontrolled BP at study end. However, by Students t-test, the means of controlled vs uncontrolled are
significantly different, Po0.05.)
60.0
55.0
50.0
45.0
% on Adequate Treatemnt
40.0
Controlled
Uncontrolled
35.0
30.0
25.0
20.0
15.0
Controlled Mild Moderate Severe Persistent Recurrent Isolated Spike
BP Category
Figure 2 Adequacy of blood pressure (BP) treatment at study end by highest preceding BP category and final BP control. Bars represent
95% confidence intervals.
Similarly, among those with severe hypertension, National Health and Nutrition Examination Survey
those with recurrent or persistent elevations were data likewise found age and being black were
older and women. The recurrent group had more associated with poorer control.22,23 An analysis of
medical comorbidities than those with persistent data from the Antihypertensive and Lipid-Lowering
elevations or the isolated severe group. Analyses of Treatment to Prevent Heart Attack Trial, additionally